Does tranexamic acid reduce elbow swelling and improve early function following arthroscopic arthrolysis? A double-blind randomized controlled trial.

ABSTRACT

BACKGROUND: Tranexamic acid (TXA) reduces bleeding and hematoma rates in open elbow arthrolysis. However, its effects on arthroscopic elbow arthrolysis remain unclear. This study aims to evaluate the effect of TXA on elbow arthroscopic procedures and compare bleeding volume, hemarthrosis, visual analog scale (VAS) for pain, range of motion (ROM), and Mayo Elbow Performance Score (MEPS) in the early postoperative period between patients who received intra-articular TXA and those who did not. METHODS: A prospective, double-blind, randomized controlled trial enrolling 80 patients with stiff elbows who underwent arthroscopic arthrolysis was performed from January 2021 to December 2022. Intra-articularly, 1 g of TXA in 100 ml of saline or placebo (control group) was administered after the arthroscopic operation according to randomization. Parameters were recorded and compared between the groups, including bleeding volume of drainage, hemoglobin (Hgb) level, ratio of arm and forearm circumference of the surgical side to the contralateral side, grading of hematoma, VAS, ROM, and MEPS within 1 week postoperatively. And during 1 year follow-up, ROM and MEPS were recorded. RESULTS: All patients enrolled in this study demonstrated significant improvements in ROM (flexion-extension) and MEPS 1 week postoperatively, with no significant differences observed between the 2 groups. Compared to the control group, the TXA group exhibited significant differences in the bleeding volume of drainage (61.45 ± 47.7 ml vs. 89.8 ± 47.0 ml, P = .030) and a higher Hgb level 24 hours postoperatively (13.5 ± 1.5 g/dL vs. 12.6 ± 1.8 g/dL P = .049). While the ratio of arm and forearm circumferences significantly increased 24 hours postoperatively compared to preoperative values in TXA group (1.05 ± 0.06 vs. 1.02 ± 0.04 and 1.02 ± 0.06 vs. 0.98 ± 0.04, with P = .019 and P = .005, respectively), this difference vanished 1 week postoperatively for the ratio of arm circumference. However, it persisted for the ratio of forearm circumference (1.02 ± 0.07 vs. 0.98 ± 0.04, P = .003). Furthermore, there was no significant difference in MEPS, VAS, or ROM between the 2 groups 1 week postoperatively. CONCLUSION: Patients with stiff elbows who underwent arthroscopic arthrolysis achieved satisfactory clinical outcomes very early postoperatively. Compared to the control group, patients who underwent arthroscopic elbow arthrolysis with intra-articular administration of TXA exhibited significantly less bleeding volume of drainage and slightly higher Hgb levels postoperatively. One week postoperatively, slightly more swelling in the upper arm region was noted in the control group compared to the TXA group. These findings suggest that the intra-articular injection of TXA after arthroscopic release for elbow stiffness may statistically reduce complications related to postoperative bleeding. However, it's clinical relevance needs further investigation.